Coenzyme Q10 was snapped up, and related concept stocks attracted attention!

On January 11, coenzyme Q10 related topics were on the hot search, and related concept stocks also gained attention
.
In terms of individual stocks, Jindawei, Xinhe Chengjun rose slightly on the morning of the 11th, while Lily Shares, Zhejiang Pharmaceutical, Tomson By-Health, etc.
all fell
.
Among the rising stocks, as of 11:31, Jindawei rose slightly by 0.
87%, quoting 23.
08 yuan, with a turnover of 213 million, a turnover rate of 1.
52%, and a price-to-earnings (TTM) of 29.
81
.
As of 11:31, Xinhecheng rose 0.
53%, the quotation was 18.
98 yuan, the turnover was 77.
1 million, the turnover rate was 0.
13%, and the price-to-earnings (TTM) was 14.
88
.
In terms of falling stocks, Zhejiang Pharmaceutical fell -0.
17% as of 11:31, with a quotation of 11.
90 yuan, a turnover of 37.
94 million, a turnover rate of 0.
33%, and a price-to-earnings (TTM) of 14.
74
.
As of 11:31, Tomson By-Health fell slightly -0.
53%, quoted 24.
29 yuan, with a turnover of 138 million, a turnover rate of 0.
51%, and a price-to-earnings (TTM) of 26.
26
.
As of 11:31, Lily shares fell -3.
79%, the quotation was 46.
14 yuan, the turnover was 74.
67 million, the turnover rate was 10.
06%, and the price-to-earnings (TTM) was 21.
60
.
.
.
.
.
.
.
.
Public information shows that coenzyme Q10, commonly known as vitamin Q, the English name is coenzyme Q10, alias ubiquinone, decene quinone
.
Coenzyme Q10 is a compound integrating medical and nutritional health care, which has the functions of antioxidant, activating cellular respiration, improving human immunity, etc.
, and has application value
in food, medicine, cosmetics and other fields.
On the news, the recent outbreak of demand for heart health care among Yangkang people, including the rush to buy Q10 coenzymes on online and offline platforms, and some platforms have even been out of stock, which has driven the popularity of related concept stocks
.
Among them, the head enterprise Jindawei, as a global coenzyme Q10 head supplier, has attracted the attention of investors, and has repeatedly responded to investors' concerns
on the interactive platform in recent days.
For example, on January 9, the company said on the interactive platform that Doctor's Best is a 96.
1% stake in the company's controlled U.
S.
subsidiary, and that the brand's Coenzyme Q10 is manufactured in the U.
S.
and shipped from the U.
S.
, and the company's profit is consolidated in the parent company's statement
.
The company's coenzyme Q10 also has the domestically produced "Jinlexin" brand
.
On the same day, King Dawei said on the interactive platform that in the face of the current situation that coenzyme Q10 is seriously out of stock on Taobao and Jingdong, the company's products still have 200mg specifications to purchase, and other specifications will be replenished
as soon as possible.
Previously, on January 6, King Dawei replied to investors that due to the increase in consumption, the company has increased
orders for coenzyme Q10 in recent days.
The company's coenzyme Q10 products have always been best-selling products, and the sales volume of e-commerce platforms such as Amazon and iHerb in the United States have been ahead for many years, and it has also established the first brand image
on domestic mainstream cross-border e-commerce platforms.
The company is the world's largest producer
of Coenzyme Q10.
According to the financial report, King Dawei's main product is coenzyme Q10, and its revenue in the first three quarters of 2022 was 2.
305 billion yuan, down 14.
78% year-on-year; the net profit attributable to the parent was 349 million yuan, down 47.
59% from the same period last year; Non-net profit was 346 million yuan, down 47.
46%
from the same period last year.
In addition to King Dawei, it is reported that Lily shares said that orders for products including coenzyme Q10 have increased sharply recently, and the supply of products has exceeded demand, and the company has produced
at full capacity by adjusting production lines.
In order to ensure the interests of distributors and consumers, the company said that it has not adjusted the price
of its products for the time being.
Tomson By-Health also said that it will make timely production adjustments
as demand changes.
By-Health CoQ10 raw materials are imported from Japan, usually under an annual purchase agreement
.
The company said that the price of raw materials has not increased for the time being, and the current supply of raw materials is stable, and the hot sales of terminal products are only half a month, and it takes a certain amount of time
to transmit to the upstream.
Similarly, the price of the company's preparations did not increase
.
It is worth mentioning that coenzyme Q10 only plays an adjuvant role in myocarditis and does not prevent myocarditis
.
The industry pointed out that the recent changes in related concept stocks are mainly affected
by market speculation.
But not considering the heart health care needs of Yangkang group, in recent years, with the aging of the population, the continuous upgrading of consumption, the rapid growth of demand for medicine, health products and other products, but also driven the growth
of coenzyme Q10 demand in China.
According to data from Zhiyan Consulting, as of 2021, the demand for coenzyme Q10 in China has increased to 212.
69 tons, and the compound growth rate of China's coenzyme Q10 demand has reached 18.
52%
since 2014.
In 2021, the market size of China's coenzyme Q10 industry increased to 426 million yuan, and the compound growth rate of the market size of China's coenzyme Q10 industry since 2014 was 21.
82%.

Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.